INmune Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45782T1051
USD
1.88
0.31 (19.75%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Seer, Inc. (California)
Graphite Bio, Inc.
Heron Therapeutics, Inc.
TriSalus Life Sciences, Inc.
Trevi Therapeutics, Inc.
Design Therapeutics, Inc.
Altimmune, Inc.
Vor Biopharma, Inc.
INmune Bio, Inc.
BioVie, Inc.
Vaxxinity, Inc.
Why is INmune Bio, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is INmune Bio, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
INmune Bio, Inc.
-63.64%
-0.78
106.49%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
0.98%
EBIT Growth (5y)
-216.31%
EBIT to Interest (avg)
-25.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.76%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-3.80
EV to EBITDA
-3.80
EV to Capital Employed
15.04
EV to Sales
157.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-396.14%
ROE (Latest)
-137.49%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
NET SALES(HY)

At USD 0.05 MM has Grown at 257.14%

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -114.05 %

OPERATING PROFIT(Q)

Highest at USD -8.06 MM

PRE-TAX PROFIT(Q)

Highest at USD -7.94 MM

NET PROFIT(Q)

Highest at USD -7.94 MM

-6What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -32.2 MM

ROCE(HY)

Lowest at -168.34%

EPS(Q)

Lowest at USD -1.05

Here's what is working for INmune Bio, Inc.
Net Sales
At USD 0.05 MM has Grown at 257.14%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Operating Profit
Highest at USD -8.06 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -7.94 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -7.94 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -114.05 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for INmune Bio, Inc.
Operating Cash Flow
Lowest at USD -32.2 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

EPS
Lowest at USD -1.05
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)